You are here: Industry Insights > Ritonavir

News List

Ascletis announces signing of Ritonavir tablet purchase agreement with Phokam Pharmaceutical ExpressPharma
January 20, 2022
Ascletis Pharma Inc recently announced the signing of the Ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export (as buyer) of Laos and Ascletis Pharmaceuticals (as seller), a wholly-owned subsidiary of Ascletis Pharma Inc.
Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus prnasia
January 04, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection.
Ascletis expands ritonavir oral tablets production amid Covid-19 surge pharmaceutical-business-review
January 03, 2022
ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.
Pfizer to allow generic COVID pill in 95 countries ExpressPharma
November 18, 2021
Pfizer and the UN-backed Medicines Patent Pool announced a voluntary licence yesterday on Pfizer’s generic version of COVID pill. As the pandemic continues, and in light of the ongoing inequity in global vaccine access...
Lopinavir-ritonavir not an effective treatment for COVID-19, study shows europeanpharmaceuticalreview
October 16, 2020
A clinical trial in the UK has shown that lopinavir-ritonavir is not an effective treatment for patients admitted to hospital with COVID-19.
Mylan Waives Marketing Exclusivity in US for Lopinavir/Ritonavir for COVID-19 Needs americanpharmaceuticalreview
March 31, 2020
Mylan announced, in its ongoing effort to support patients and public health needs in the current circumstances surrounding the COVID-19 pandemic.
AbbVie’s HIV drug combo shows no benefit in Covid-19 trial pharmaceutical-technology
March 20, 2020
A clinical trial in Covid-19 patients in China has yielded no therapeutic benefits with AbbVie’s HIV drug combination of lopinavir and ritonavir, marketed as Kaletra.
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia PRNewswire
February 27, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today the advancement in Novel Coronavirus Pneumonia clinical trial of oral Ganovo® and Ritonavir combination therapy, led by Dr. Hongyi CHEN, the director of the Ninth Hospital of Nanchang.